Neuroblastoma (NB) is an embryonal tumor and possesses a unique propensity to exhibit either a spontaneous regression or an unrestrained growth. However, the underlying mechanism for this paradoxical clinical outcome remains largely unclear. Quantitative RT-PCR analysis on 102 primary NB tumors revealed that lower Krü ppel-like factor 4 (KLF4) expression is frequently found in the unfavorable NB (Mann-Whitney test, P ¼ 0.027). In particular with the high-risk factors such as age of patient 41 year, MYCN amplification and low TRKA expression, the decreased expression of KLF4 was significantly associated with an unfavorable NB outcome. Despite knockdown of KLF4 alone is not sufficient to increase tumorigenicity of NB cells in vivo, stable expression of KLF4 short hairpin RNA in Be(2)-C cells significantly promoted growth of NB cells and inhibited cell differentiation toward fibromuscular lineage. In concordant with these observations, overexpression of KLF4 in SH-SY-5Y cells profoundly suppressed cell proliferation by direct upregulation of cell-cycle inhibitor protein p21 WAF1/CIP1 , and knocking down p21 WAF1/CIP1 could partially rescue the suppressive effect of KLF4. Importantly, KLF4 overexpressing cells have lost their neuroblastic phenotypes, they were epithelial-like, strongly substrate-adherent, expressing smooth muscle marker and became non-tumorigenic, suggesting that KLF4 expression is crucial for lineage determination of NB cells, probably, favoring spontaneous tumor regression. Subsequent global gene expression profiling further revealed that transforming growth factor beta (TGFb) and cell-cycle pathways are highly dysregulated upon KLF4 overexpression, and myogenic modulators, MEF2A and MYOD1 were found significantly upregulated. Taken together, we have demonstrated that KLF4 contributes to the favorable disease outcome by directly mediating the growth and lineage determination of NB cells.
INTRODUCTION
Neuroblastoma (NB) is the most common pediatric solid tumor and accounts for 15% of the childhood cancer deaths. NB is characterized by an unpredictable clinical course, some tumors possess propensity to regress either spontaneously or as a result of treatment, while others are relentless and result in poor survival. This behavior poses a challenge to the clinicians when it comes to balance long-term health risks posed by treatment against the risk of tumor progression. Therefore, identification of reliable prognostic markers would be useful in the clinic to adjust treatment strategies for children with NB. Several prognostic markers including the age of the patient at diagnosis, MYCN amplification and TRKA expression, have been described to predict the clinical outcome of NB. In particular, age 41 year 1,2 and MYCN amplification [3] [4] [5] [6] [7] [8] are strongly associated with advanced disease stages and poor disease outcome. On the other hand, TRKA, EPHB6, EFNB2 and EFNB3 were defined as favorable NB genes and high expressions of these genes are associated with good prognosis. 9, 10 It is believed that TRKA and EPHB signal pathways suppress NB growth by promoting terminal differentiation 11, 12 and restricting growth, angiogenesis and metastasis of NB cells, 10 respectively. More recently, a causal link between MYCN activity and TRKA repression has also been established, suggesting that MYCN may contribute to the tumor aggressiveness by repressing TRKA expression through directly targeting its proximal/core promoter regions. 13 Recent advances in whole-genome profiling have brought new insights for NB patient stratification, unique genomic/expression signatures were identified and associated with specific abnormalities and distinct prognosis. [14] [15] [16] [17] [18] [19] [20] Emerging evidence have suggested that NB cells carrying unique genetic makeup may favor these cells to differentiate further to different lineages and contribute to the enigmatic and paradoxical clinical outcomes of the tumors. 21 Fibromuscular lineage differentiation may cause tumor regression, while NB cells committed to the neuronal lineage would acquire additional genetic changes that may favor tumor progression, leading to an unfavorable outcome. 22, 23 Nevertheless, factor(s) mediating these differentiation processes that may be implicated in tumor regression/progression has yet been identified. Unraveling these molecular mechanisms underlying tumor regression/progression would open up for prognostic and therapeutic interventions.
Krü ppel-like factor 4 (KLF4) is a transcriptional factor that mediates a set of cell-cycle genes and exhibits both oncogenic or tumor suppressive functions in different contexts. 24 In colorectal and gastric cancers, KLF4 promoter is frequently methylated and results in loss of its expression. In vivo study consistently demonstrated that overexpression of KLF4 in colonic and gastric cancer cells reduces their tumorigenicity. 25, 26 Conversely, oncogenic function of KLF4 was demonstrated in squamous-cell carcinoma of the oropharynx, 27 ectopic KLF4 expression in mice induced squamous epithelial dysplasia. 28 For breast cancer, the role of KLF4 is less clear. On one hand, elevated KLF4 levels have been detected in breast cancer and KLF4 was shown to be crucial for maintenance of cancer stem cells of the tumors, 29, 30 while other studies supported KLF4 as a tumor suppressor. 31, 32 In addition to its context-dependent oncogenic and tumor suppressive functions, Klf4 also has a peculiar role in the process of cell differentiation. On one hand, it is implicated in promoting differentiation of post-mitotic cells. In mice, ectopic expression of Klf4 accelerates terminal differentiation, leading to premature skin-barrier acquisition, 33 whereas Klf4 deficiency prevents the terminal differentiation of colonic goblet cells 34 and the skin epithelium. 35 KLF4 also represents a critical regulator in controlling monocyte differentiation 36 and smooth muscle cell fate commitment of cephalic neural crest. 37 In addition, a recent study also showed that KLF4 inhibits epithelial-mesenchymal transition of breast epithelial cells through maintaining E-cadherin expression. 38 During the process of reprogramming somatic cells to resume their stem cell nature (that is, dedifferentiation), KLF4 is particularly implicated in the initial phase of reprogramming to initiate mesenchymal-toepithelial transition by inducing epithelial gene expression. [39] [40] [41] Therefore, KLF4 might mediate not only the cell-cycle progression of the tumor cells, but also their differentiation status, although the underlying molecular mechanisms remain largely undefined. In this study, we assessed the role of KLF4 in NB prognosis. With in vitro and in vivo models, its functional impacts on NB tumor growth, differentiation and the underlying molecular mechanisms were elucidated.
RESULTS
Reduced KLF4 expression is associated with poor NB outcome To examine whether the expression of KLF4 is associated with tumor progression of NB, 102 NB tumor tissue were collected and subjected to expression analysis using real-time RT-PCR. We then stratified the NB cohort into favorable (n ¼ 47; Stages 1, 2 and 4S) and unfavorable (n ¼ 55; Stages 3 and 4) groups according to International Neuroblastoma Staging System stage of NB. The result shown in Figure 1a suggests that KLF4 expression in the favorable group is significantly higher than those in the unfavorable group (Mann-Whitney test, P ¼ 0.027). Nevertheless, when we further stratified the cohort into different stages, no significant association between expression of KLF4 and tumor stages was observed (data not shown).
In fact, our data also revealed that KLF4 expression is significantly predictive of disease outcome of the unfavorable NB cohort by dichotomization (Figures 1b and d) . Using the Kaplan-Meier method, survival probabilities of high and low expression (the median of KLF4 expression level was used as the cutoff value) subgroups for KLF4 was estimated and survival of groups were compared by log-rank tests. As shown in Figure 1 , high KLF4 expression was associated with better disease outcome of patient of low TRKA expression (Figure 1b , P ¼ 0.015), of age over 1 year (Figure 1c , P ¼ 0.006), and of MYCN amplification (Figure 1d , P ¼ 0.013). These results indicate that high-level KLF4 expression is a favorable feature of high-risk NB.
To gain insight into the independent prognostic significance of KLF4 expression in the overall patient cohort, multivariate analysis was performed. Age at diagnosis (X1 vs o1 year), MYCN amplification status (amplified vs normal), origin of the tumor (adrenal gland vs others), metastasis status (metastasized vs non-metastasized), dichotomized TRKA expression and dichotomized KLF4 expression Figure 1 . Effect of KLF4 expression on disease outcome of high-risk NB. (a) Study cohort was stratified into favorable and unfavorable according to International Neuroblastoma Staging System (favorable: n ¼ 47; Stages 1, 2 and 4S; unfavorable: n ¼ 55; Stages 3 and 4). MannWhitney test indicates that high KLF4 expression is associated with favorable features of NB. (b-d) Kaplan-Meier survival analysis was employed to assess survival probabilities of NB with unfavorable features: (b) low TRKA expression, (c) age over 1 year and (d) MYCN amplification. The cutoff value 0.14 (median of KLF4 expression level) was used to dichotomize the study cohort as indicated.
were tested in a Cox proportional hazards models and statistically significant variables were retained ( Table 1) . As shown in Table 1 , KLF4 expression remained a highly significant independent indicator (P ¼ 0.016). In addition, metastasis status (P ¼ 0.001), TRKA expression (P ¼ 0.011) and MYCN amplification status (P ¼ 0.010) also contributed significant predictive power in determining NB outcome. Nevertheless, no independent prognostic impact for age at diagnosis and origin of the tumors has been observed.
KLF4 overexpression reduces tumorigenicity of NB cells in transformation assays
In this study, four representative NB cell lines of distinct morphologic, differentiative and tumorigenic properties were used. They were SH-SY-5Y (N-type: neuroblastic), BE(2)C (I-type: stem cell-like), SK-N-AS (S-type: epithelial-like substrate-adherent) 42, 43 and SK-N-SH (mixed phenotypes) ( Table 2 ). Quantitative RT-PCR analysis revealed that KLF4 is expressed in three NB lines including BE(2)C, SK-N-AS and SK-N-SH, but its expression is barely detected in SH-SY-5Y cells (Figure 2a) .
To elucidate the biological implications of KLF4 in NB, we first overexpressed FLAG-tagged KLF4 transgene in SH-SY-5Y and generated KLF4 overexpressing stable transfectants (FLAG-KLF4). In parallel, control stable transfectants that were transfected with the empty vector (Vector Ctrl) were also obtained. Bromodeoxyuridine (BrdU) proliferation assay showed that KLF4 overexpressing cells (FLAG-KLF4) proliferate significantly slower than the control cells (Vector Ctrl) (Po0.01, Figure 2b ).
As revealed in soft agar colony formation assay, overexpression of KLF4 profoundly suppressed anchorage-independent growth of SH-SY-5Y. The control group could grow and form colonies in the soft agar, while no colony was observed with KLF4 overexpressing cells after culturing for 6 weeks (Figure 2c ). The in vivo tumorigenicity of the stable clones was further examined by inoculating the cells subcutaneously ( Figure 2d ) and orthotropically (Figure 2e ) into the flank and adrenal fat pads, respectively, of SCID-Beige mice. At 90 days post injection, the control clone generated tumors in all four mice (Figure 2d ), whereas no tumor was found in the KLF4 overexpressing group (Figure 2d ). Dramatic suppression of tumor formation was also observed in mice subjected to orthotropic injections (n ¼ 7). Tumors were observed in all mice injected with the control cells (Vector-Ctrl), but none of the mice injected with KLF4 overexpressing cells (FLAG-KLF4) bears tumor by 100 days after injection (Figure 2e ). Downregulation of KLF4 promotes NB cell growth, but is not sufficient to induce tumor To investigate whether loss of KLF4 contributes to the aggressive phenotypes of NB cells, stable BE(2)C KLF4 knockdown (shKLF4#1 and shKLF4#2) and control (NS#1 and #2) clones were established using lentivirus expressing KLF4-specific shRNA and the control non-silencing shRNA (NS), respectively. BrdU proliferation assay revealed that knockdown of KLF4 significantly enhances the proliferation of NB cells (Figure 3a) . In addition, both knockdown clones (shKLF4#1 and shKLF4#2) grew significantly faster than the control clones (NS#1 and NS#2) (Figure 3b ). Nevertheless, KLF4 knockdown clone (shKLF4#1) did not generate tumors substantially faster than those derived from the control clone (NS#2) when they were injected in the SCID/Beige mice (data not shown).
Expression of KLF4 is required for the non-tumorigenic lineage differentiation of NB cells It is known that NB cells retain differentiation plasticity and differentiation to fibromuscular lineage may result in tumor regression. To test if KLF4 affects lineage determination of NB cells, we further analyzed the differentiation plasticity of the KLF4 overexpressing SH-SY-5Y cells and BE(2)C knockdown clones using various makers. SH-SY-5Y is mainly constituted of N-type NB cells. As expected, SH-SY-5Y cells stably transfected with empty vector (Vector Ctrl) exhibited neuroblastic morphology and did not express smooth muscle marker (smooth muscle actin (SMA) negative) or focal adhesion proteins (paxillin and phalloidin negative) (Figure 4a ). Intriguingly, KLF4 overexpressing clones (FLAG-KLF4) exhibited a substantial morphological change. Cells lost their neuroblastic phenotypes, they were epithelial-like, strongly substrate-adherent, expressing SMA and paxillin. Western blot analysis further showed that paxillin is not only upregulated, but also highly phosphorylated in the KLF4 overexpressing clone (FLAG-KLF4) (Figure 4b ).
To directly demonstrate the role of KLF4 in fibromuscular differentiation, we cultured BE(2)C stable clones that mainly comprised I-type cells, in differentiation medium containing 10 mM BrdU to induce fibromuscular lineage differentiation. Two weeks after induction with BrdU, the control clones transduced with NS (10 mM BrdU) exhibited remarkable morphological change when compared with the untreated control (Figure 4c , NS, Ctrl). Similarly to KLF4 overexpressing SH-SY-5Y cells, BrdU-treated BE(2)C cells became flatten and were epithelial cell like, whereas this difference was not observed in the knockdown clones (shKLF4, Ctrl and 10 mM BrdU). To further monitor fibromuscular lineage differentiation, BE(2)C was stained with SMA ( Figure 4d Intriguingly, KLF4 did not alter the neuronal differentiation capacity of these cells. BE(2)C non-silencing and stable knockdown KLF4 mediates growth and lineage determination of NB cells CKY Shum et al clones were treated with retinoic acid for 4 weeks. The neuronal differentiation was then monitored by the presence of neurite outgrowth. Four weeks after treatment, both control and knockdown clones could generate neurite outgrowth at a similar extent (Figure 4e ), suggesting that KLF4 may not directly contribute to the neuronal differentiation of NB cells.
KLF4 upregulates p21 WAF1/CIP1 expression, but not p53 in NB cells
Given that KLF4 has been shown to upregulate the CDK2 inhibitor p21 WAF1/Cip1 and repress p53 suppressor to induce growth arrest, we then examined if KLF4 mediates the expression of these two cell-cycle regulators in NB cells. As revealed by western blot analysis, elevated expression of p21 WAF1/Cip1 was observed in the KLF4 overexpressing clone (FLAG-KLF4), while CYCLIN D2 was substantially downregulated in these cells (Figure 5b ). Nevertheless, p53 expression was not affected (Figure 5a ).
To test whether KLF4 upregulates p21 WAF1/Cip1 expression by direct activation of gene transcription, we transfected SK-N-AS cells with a plasmid encoding firefly luciferase under the control of a p21 WAF1/CIP1 (p21-Luc) or p53 (p53-Luc) promoters, expression vectors for wild-type KLF4 or KLF4 mutant with partial deletion on (e) SH-SY-5Y stable transfectants were injected orthotropically into adrenal fat pad of each mouse. Mice were killed at 2 months (n ¼ 4) or 100 days (n ¼ 3) after injection and tumors were observed in the control group, but not in the KLF4 overexpressing group. A representative picture of mice killed at day100 is shown. The values reported in the bar graphs represent the mean±95% CIs from three independent assays, each in triplicate. Data were analyzed by two-sided unpaired Student's t-tests, and P-values o0.05 were considered to be statistically significant. activation domain (KLF4DA) or KLF4 mutant with a complete deletion of DNA-binding domain (KLF4DDBD), or the control empty vector (pFLAG-CMV), and a plasmid encoding Renilla luciferase (pRL-SV40). The extents to which KLF4 and its mutants transactivated the p21 WAF1/CIP1 and p53 promoters were assessed by normalizing firefly luciferase activity to Renilla luciferase activity. Overexpression of KLF4 significantly activated p21 WAF1/CIP1 transcription, while its transactivity has been partially or completely abolished when the activation domain or DNA-binding domain was deleted, respectively ( Figure 5c ). In contrast, there is no transactivation activity detected with the p53 reporter (Figure 5c ). This finding is consistent with the western blot data, suggesting that KLF4 directly upregulates p21
, but not p53. Importantly, knocking down p21 WAF1/CIP1 in the KLF4 overexpressing cells could significantly increase the proliferation rate of these cells, suggesting that p21 WAF1/CIP1 is implicated in the KLF4 mediated growth suppression (Figure 5d ).
In NB, p53 is mainly implicated in regulation of apoptosis. To address if tumor suppressive effect of KLF4 also relies on p53 induced apoptosis, an NB line, SK-N-AS, of exon 9 deletion in the p53 gene was used. Annexin V apoptosis assay revealed that overexpression of KLF4 could significantly (but slightly) induce apoptosis of SK-N-AS (P ¼ 0.044), whereas transfection with KLF4DA or KLF4DDBD expression construct did not increase apoptotic cells in the culture (Figure 5e ). It is noteworthy that similar result was observed with SH-SY-5Y, which carries the wild-type p53 (Supplementary Figure 1) .
In regard to cell growth, overexpression of KLF4 could profoundly inhibit cell growth of SK-N-AS as indicated in the colony formation assay. Overexpression of wild-type KLF4, but not the mutants (KLF4DA and KLF4DDBD) resulted in a dramatic reduction in number as well as the size of colonies obtained (Figure 5f ). In concordance with these observations, transient Values reported in the graphs represent the mean±95% CIs from three independent assays, each in triplicate. Data were analyzed by two-sided unpaired Student's t-tests, and P-values o0.05 were considered to be statistically significant.
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knockdown of KLF4 in SK-N-SH cells that express wild-type p53 also significantly promoted the cell growth as indicated in the proliferation assay (Figure 5g ). Therefore, all these data suggest that p21 WAF1/CIP1 -dependent growth retardation may represent one of the predominant mechanisms by which KLF4 inhibits NB cell growth. KLF4 
To further delineate the underlying molecular pathways implicated in KLF4 induced fibromuscular differentiation and retarded growth of NB cells, global gene expression profiles of SH-SY-5Y cells stably transfected with pFLAG-CMV-KLF4 (FLAG-KLF4) or pFLAG-CMV (Ctrl) construct were compared. The microarray analysis revealed that 11 448 genes are differentially expressed (Po0.01) in KLF4 overexpressing and control clones. Seventythree percent of these genes showed greater than twofold changes in either direction, 35.3 and 24.8% were found to be upregulated and downregulated, respectively. Subsequent pathway-based analysis further identified that transforming growth factor beta (TGFb) pathway genes are highly dysregulated in the KLF4 overexpressing cells (Figure 6a ; Tables 3 and 4 ). They included TGFb receptors (TGFBR1, 2 and 3), its signal transducer (SMAD 2, 3, 4, 5, 6, 7, 9), co-factor (LEF1 and ZNF423), repressor (ZFHX1B) and effector genes (SERPINE1 and SKIL). In addition, two key myogenic regulators (myocyte enhancer factor 2, MEF2; myogenic differentiation 1, MYOD1) and fibromuscular differentiation markers (S100 and SM22) were found upregulated in KLF4 overexpressing SH-SY-5Y. Calcium calmodulin-dependent protein kinase (CAMK2), an upstream regulator for MEF2, was also elevated.
In regard to cell-cycle progression, elevated expression of p21 WAF1/CIP1 (2.4-folds) and cell-cycle checkpoint kinase (ATM, 2.9-folds) and repression of mitotic check point regulators (CDC20 and hBUBR1) were also detected in the KLF4 overexpressing cells, accounting for the retarded cell growth (Figure 6b) .
In summary, overexpression of KLF4 in SH-SY-5Y cells altered both TGFb and cell-cycle pathway genes. In particular, the specific composition of TGFb-induced SMAD transcription factor complexes seems to be an important determinant to turn on the myogenic regulators (MEF2A and MYOD1), promoting fibromuscular differentiation of NB cells. In parallel, dysregulation of cell-cycle pathway genes (p21 WAF1/CIP1 and CDC20) may lead to retarded cell growth (Figure 6c ).
DISCUSSION
The bipotent plasticity of NB cells to neuronal and fibromuscular lineages is believed to account for the diverse clinical outcomes of NB. 22, 23, [42] [43] [44] [45] As the bipotent progenitor cells possess high clonogenicity, they would generate a vast population of neuronal committed cells and contribute to the bulk tumor. On the other hand, if these NB cells differentiate to fibromuscular cells, then it may result in tumor regression. Therefore, genetic alternations that favor NB progenitors to differentiate toward neuroblastic lineage may promote tumor progression, while to fibromuscular lineage may lead to a favorable clinical outcome.
In this study, we demonstrated that KLF4 represents a favorable gene for NB and loss of KLF4 expression is usually associated with poor prognosis, particularly in the high-risk patient of age older than 1 year, low TRKA expression or with MYCN amplification. Cox regression model further suggested that KLF4 expression, TRKA expression, metastasis and MYCN amplification status contribute independent predictive power in determining tumor outcome. Indeed, our functional data also indicated that KLF4 may function independent of these pathways. Overexpression of KLF4 in SH-SY-5Y cells induced morphological change of the cells accompanied by upregulation of focal adherent protein (paxillin). Nevertheless, these changes did not alter the cell motility. With transwell migration assay, we found that the KLF4 overexpressing SH-SY-5Y and the control clones exhibit similar motility (Supplementary Figure 2) . In addition, expression profiling analysis on a panel of NB cell lines also revealed that there is no obvious association between KLF4 and MYCN expression (Supplementary Figure 3) . MYCN has been shown to directly suppress TRKA expression, but suppressive effect of MYCN on KLF4 expression was not observed. Using the Tet21N(-) NB cells that harbor a tetracycline-inducible MYCN transgene, 46 we found that tetracycline induced overexpression of MYCN did not alter KLF4 expression (Supplementary Figure 4) , indicating that MYCN does not directly regulate KLF4 expression.
On the other hand, we demonstrated that KLF4 reduces NB cell growth, mediates terminal differentiation to fibromuscular lineage and the cell-cycle progression as well as induces apoptosis of NB cells. Here, we used four NB cell lines representing neuroblastic (SH-SY-5Y, N-type), fibromuscular (SK-N-AS, S-type), stem cell-like (BE(2)C, I-type) and mixed (SK-N-SH, mixed) populations of NB to elucidate how KLF4 may affect different cell compartments of NB and contribute to good prognosis. Despite SH-SY-5Y comprises majority of neuroblastic cells, previous subcloning studies indicated it also contains a small population of bipotent progenitors, representing an excellence experimental model for NB. Dynamic interconversion between different cell sub-populations has also been demonstrated, the progenitors provide an indefinite replenishment of the neuroblastic bulk population, whereas they also rely on the neuroblastic cells for their maintenance. Removal of the neuroblastic sub-population will purge the progenitors and induce their terminal commitment to the fibromuscular phenotypes, resulting in spontaneous regression of NB. 23 When we stably overexpressed KLF4 in SH-SY-5Y, all the KFL4 expressing transfectants exhibited an epithelial-like phenotypes and some even expressed fibromuscular marker. Importantly, these cells were totally non-tumorigenic in vivo. These observations prompted us to speculate if (i) KLF4 overexpression induces apoptosis of neuroblastic cell compartments and indirectly drive progenitors toward to fibromuscular differentiation; (ii) stable change in KLF4 expression favors the outgrowth of a minority WAF1/CIP1 and p53 enhancers. Schematic diagram summarizes the expression constructs for the wild-type KLF4 and KLF4 deletion mutants. KLF4DA bears a partial deletion of the activation domain and KLF4DDBD has a complete deletion of the DNA-binding domain (DBD). Reporter plasmids encoding luciferase under the control of p21 WAF1/CIP1 and p53 enhancers, p21-Luc and p53-Luc, respectively, were transfected into SK-N-AS along with an internal control plasmid encoding Renilla luciferase pRL-SV40, and either a plasmid encoding wild-type KLF4 (pFLAG-KLF4), KLF4DA (pFLAG-KLF4DA), KLF4DDBD (pFLAG-KLF4DDBD) or empty vector (pFLAG-CMV). Promoter activity is expressed as relative luciferase activity after normalization to Renilla activity. (d) Annexin V apoptosis assay. (e) SK-N-AS cells were transiently transfected with empty vector (pFLAG-CMV), KLF4 (pFLAG-KLF4), KLF4DA (pFLAG-KLF4DA) or KLF4DDBD (pFLAG-KLF4DDBD). The late apoptotic cells (Annexin V and propidium iodide double positive) were quantified using flow cytometry. (f) Colony formation assay. SK-N-AS cells transiently transfected with empty vector, wild-type or mutant KLF4 expression constructs were plated at the same density and grown in selection medium for 2 weeks. Colonies were stained and photographed. Representative pictures from each group were shown. The experiments were repeated three times with triplicate. Lower panel: Quantitative data are shown. (g) Upper panel: BrdU incorporation assays on the SK-N-SH cells transfected with non-silencing siRNA (NS) and KLF4 siRNA (siKLF4). Lower panel: RT-PCR analysis of the expression of KLF4 in the siKLF4 and non-silencing siRNA transfected cells. The values reported in the bar graphs represent the mean±95% CIs from three independent assays, each in triplicate. Data were analyzed by two-sided unpaired Student's t-tests, and P-values o0.05 were considered to be statistically significant. A full colour version of this figure is available at the Oncogene journal online.
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population; or (iii) KLF4 has an active role to direct fibromuscular differentiation. To address this question, the apoptotic potential of KLF4 was tested. Our data from Annexin V apoptosis and growth assays indicated that KLF4 indeed can slightly induce apoptosis, while its inhibitory effect on cell growth mainly relied on the upregulation of p21 WAF1/CIP1 expression in SH-SY-5Y and SK-N-AS cells. Knocking down p21 WAF1/CIP1 could partially rescue the suppressive function of KLF4 in cell proliferation. In line with these KLF4 mediates growth and lineage determination of NB cells CKY Shum et al observations, knockdown of KLF4 in BE(2)C and SK-N-SH significantly promoted cell growth in vitro, but loss of KLF4 was not sufficient to induce tumor. Given that KLF4 exhibited similar suppressive function in NB cells containing either wild-type (SH-SY-5Y) or mutant (BE(2)C and SK-N-AS) p53, it further suggests that p53-driven apoptosis is unlikely the only mechanism by which KLF4 inhibits NB cell growth.
In regards to NB differentiation, KLF4 knockdown robustly abolished the differentiation plasticity of BE(2)C cells to commit to fibromuscular lineage, implying that KLF4 is critical for fibromuscular lineage differentiation. Despite we cannot completely rule out the possibility that KLF4 induced fibromuscular differentiation is a secondary effect of a biased selection process, with our current data and data previously published by others, 37 we believe that KLF4 is likely taking an active role in this cellular process. In particular, TGFb has been shown to induce smooth muscle cell differentiation of a non-cancerous neural crest cell line, through modulating SMAD, mitogen-activated protein kinase, phosphoinositol-3 kinase and RhoA signalings. 47 Our global gene expression profiling data also showed that TGFb pathway has been highly dysregulated in NB cells upon overexpression of KLF4, they include the TGFb receptors, various SMAD and their effector genes. Moreover, other signaling modulators implicated in smooth muscle lineage differentiation, such as MAPK (MAPK9), calcium (CAMK2) signalings were also found upregulated. CAMK2 is known to phosphorylate a series of conserved serine residue on class II histone deacetylases and promote the nuclear-tocytoplasmic shuttling of these histone deacetylases and the subsequent activation of MEF2, in turn, induce fibromuscular differentiation. 48, 49 Given that TGFb-SMAD pathways have been implicated in many biological processes and varied signaling pathways are upregulated in KLF4 overexpressing cells, it is conceivable that multiple pathways with a specific composition of various pathway genes are crucial for the smooth muscle differentiation. Noteworthy, our data suggest that two myogenic modulators, MEF2 and MYOD1, are likely the common downstream targets of these pathways for the activation of fibromuscular differentiation of NB cells. In parallel, KLF4 also directly or indirectly alters a panel of cell-cycle mediators (p21 WAF1/CIP1 , CDC20, CYCLIN D2, and so on), which may lead to retarded cell growth.
Taken together, high KLF4 expression may favor tumor regression through inducing cell-cycle arrest and fibromuscular lineage differentiation, while KLF4-deficient NB progenitors may maintain a neuroblastic bias over the KLF4 expressing counterparts. Loss of KLF4 may also promote the growth of neuroblastic cells and account for the poor prognosis. Nevertheless, whether KLF4 induced growth retardation and fibromuscular differentiation represent two divergent processes or a coordination between these two cellular processes is required for inducing NB regression remains unclear.
In summary, we have demonstrated that KLF4 is a favorable gene in NB. Integrated analysis on the expression pattern of KLF4 with other key prognostic markers might further enhance its prognostic value for the prediction of clinical outcome of Abbreviations: KLF4, Krü ppel-like factor 4; TGF, transforming growth factor. Genes implicated in myofibroblast differentiation are bolded.
KLF4 mediates growth and lineage determination of NB cells CKY Shum et al the tumors and facilitate patient stratification. In addition, our functional studies directly provide a mechanistic explanation on how KLF4 may contribute to the favorable clinical outcome and highlight the importance of two distinctive cellular processes, proliferation and differentiation, in determining the tumor behavior.
MATERIALS AND METHODS

Primary NB tumor samples
A total of 102 NB tumor specimens obtained from the Chiba Cancer Center Research Institute, Chiba, Japan, were included in this study. All subjects were unrelated ethnic Japanese and recruited in Japan between 1995 and 2003. Patients were treated by the standard protocols. 50, 51 The median age of the entire cohort was 19.5 months (range: 0-163 months). Tumors at all stages were included: Stage 1, n ¼ 27, 26.5%; Stage 2, n ¼ 15, 14.7%; Stage 3, n ¼ 32, 31.4%; Stage 4, n ¼ 23, 22.5%; Stage 4S, n ¼ 5, 4.9%. All tumors were histopathologically diagnosed as NB and were staged according to the International Neuroblastoma Staging System. 3 MYCN copy number, TRKA mRNA expression and DNA ploidy were measured as reported previously. 52 Informed consent was obtained at each institution or hospital. The procedure of this study was approved by the Institutional Review Board of the Chiba Cancer Center (CCC7817).
Quantitative reverse transcription-PCR (RT-PCR)
RNA for RT-PCR was extracted from the NB samples using TRizol Reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed in 20 ml reactions using SuperScript RNA Amplification System (Invitrogen), in accordance with manufacturer's instructions. For patient samples, quantitative PCR was performed in the Taqman universal master mix (Applied Biosystems, Foster City, CA, USA), which consisted of 1 Â mastermix, hKLF4 (Assay ID Hs00358836_m1) or GAPDH (Assay ID Hs02758991_g1) forward and reverse primers, and their probes (Applied Biosystems). For NB cell lines, quantitative PCR was performed using the Cybergreen reaction mix (Applied Biosystems), which consisted of 1 Â mastermix, KLF4 forward (5 0 -TCAGTGGCCGCCACCGTGTCC-3') and reverse (5 0 -GTGAAGCTGCAGGTG GAGGGC-3') primers or 18S forward (5 0 -CGGCTACCACATCCAAGGA-3') and reverse (5 0 -GCTGGAATTACCGCGGCT-3') primers. The reaction mix (18 ml) was aliquoted into tubes and 1 or 2 ml cDNA was added. Triplicated 20 ml samples and positive and negative controls were placed in a PCR plate and wells were sealed with optical caps. The PCRs were carried out using an ABI Prism 7500 or 7900HT (Applied Biosystems). All Taqman primers and probes were designed by Applied Biosystems. Data were analyzed and processed using Sequence Detector version 1.4 (Applied Biosystems) in accordance with manufacturer's instructions. Primers were optimized and the linearity of the results validated by serial dilution of a plasmid DNA containing hKLF4 coding sequence. Results were expressed relative to a positive standard (plasmid DNA) that was included in all reaction sets. GADPH or 18S was used as the internal control.
KLF4 expression constructs
Human cDNA for KLF4 (GenBank or RefSeq NM_004235) that contained the full-length KLF4 coding region was obtained by PCR and cloned into pFLAG-CMV2 (Sigma-Aldrich, St Louis, MO, USA). For deletion constructs, cDNAs for KLF4 deletion mutants were obtained by PCR and subcloned into pFLAG-CMV2 (Sigma-Aldrich). KLF4DA contains an N-terminal deletion of the transcriptional activation domain and is missing the first 109 amino acid. KLF4DDBD lacks the zinc-finger DNA-binding domain (amino acids 350-483). All the plasmids were verified by sequencing.
Cell lines and stable transfectants
Human NB cell lines, SK-N-SH, SH-SY-5Y, SK-N-AS and BE(2)C, from ATCC were grown in MEM or DMEM containing 10% fetal bovine serum, nonessential amino acid and 10 mM sodium pyruvate (Invitrogen). SH-SY-5Y and SK-N-AS have no MYCN amplification; SK-N-AS carries mutant p53; BE(2)C has MYCN amplification and a p53 mutation. Specific mutations in these NB cells lines are listed in Table 2 .
KLF4 overexpressing clones. pFLAG-CMV-KLF4 or pFLAG-CMV construct was transfected into 2 Â 10 5 SH-SY-5Y cells using the Amaxa Nucleofector Kit (Amaxa, Cologne, Germany) according to manufacturer's instructions and grown in DMEM selection medium containing 0.5 mg/ml G418 (Invitrogen). The cloned stable transfectants were tested for FLAG-KLF4 expression using immunoblot analysis with anti-FLAG and anti-KLF4 antibodies (as described below) and used for the subsequent experiments.
KLF4 knockdown clones. MISSION Lentiviral transduction particles expressing non-target shRNA control (SHC002V) or shRNA specifically against KLF4 (TRCN5313) were purchased from Sigma (St Louis, MO, USA). To generate the stable transduced clones, 1 Â 10 5 BE(2)C or SH-SY-5Y cells were seeded into a 35-mm well and transduced with lentiviral transduction particles expressing non-silencing control (NS, 1:100) or shKLF4 (1:20) in the presence of 2 mg/ml polybrene. After 12 h, the virus-containing medium was replaced with fresh culture medium. Four days after the transduction, cells were replated in selection medium, which consisted of full medium with the addition of 2 mg/ml puromycin (Sigma). The stable transduced clones were tested for KLF4 expression with quantitative RT-PCR.
RT-PCR
Total RNA was isolated from various NB cell lines and stable transfectants by RNeasy min kit (Qiagen, GmbH, Hilden, Germany) and reverse transcribed in 20 ml reaction system using SuperScript RNA Amplification System (Invitrogen), in accordance with manufacturer's instructions. PCRs were performed using specific primers: human KLF4 (Forward: 
Immunoblots
To examine the expression of the stable clones and the molecular pathway studies, the G418-resistant clones were isolated after growth in the selection medium for 3 weeks. Cell pellets were collected and then lysed with cell lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin and 1 mM phenylmethanesulfonyl fluoride. Cell lysates containing 20 mg of total protein were separated on 10% SDS-polyacrylamide gels and blotted onto nitrocellulose membranes. The membranes were then incubated with monoclonal antibodies against FLAG (clone M2, 1:10 000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), cyclin D1 (Cat #Sc-753, 1:1000; Cell Signaling Technology, Beverly, MA, USA), polyclonal p21 WAF1/CIP1 (12D1, Cat #2947, 1:1000; Cell Signaling Technology), p53 (7F5, Cat #2527, 1:1000; Cell Signaling Technology), pTry118paxillin (1:1000; Cell Signaling Technology Inc.) or paxillin (1:1000; Upstate, Lake Placid, NY, USA). The same membranes were stripped with stripping buffer (100 mM 2-mercaptoethanol, 2% sodium dodecyl sulfate, 62.5 mM Tris-HCl, pH 6.7), blocked and reprobed with a 1:1000 dilution of anti-b-actin monoclonal antibody (Chemicon International, Inc., Temecula, CA, USA) or a-tubulin (Sigma) to ensure equal loading of cell protein per lane. All blots were incubated with 1:5000 dilutions of secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibody (Amersham Pharmacia Biotech., Piscataway, NJ, USA). Antibody-bound proteins were visualized using a chemiluminescence system (Amersham Biosciences, Piscataway, NJ, USA).
Cell proliferation assay 1 Â 10 4 SK-N-SH cells, SH-SY-5Y transfectants or BE(2)C transduced cells were seeded per well in 96-well culture plates for 16 h before addition of BrdU. BrdU (1:1000) was added into the culture for 4 h. The cultures were fixed, blocked and incubated with anti-BrdU antibody. The cell proliferation rate was measured using Cell Proliferation ELISA kit, colorimetric (Roche, Indianapolis, IN, USA). Three independent experiments were performed, and each experiment was in triplicate.
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Growth curve assay 1 Â 10 4 BE(2)C transduced clones were seeded in 24-well plate. Cell growth of BE(2)C transduced clones was measured by counting the number of viable cells on days 2, 4, 6 and 8. In brief, cells were harvested and stained with 0.4% trypan blue and the viable cells were counted using hemocytometer. The experiments were performed three times and each in triplicate.
Colony formation assay
One day before transfection, 2 Â 10 5 SK-N-AS cells were seeded onto 35-mm plates. Two micrograms of pFLAG-CMV-KLF4, pFLAG-CMV-KLF4DA, pFLAG-CMV-KLF4DDBD (FLAG-tagged) or pFLAG-CMV expression vector was co-transfected with 0.2 mg of pcDNA3.1 vector (Promega, Madison, WI, USA) into the cells. After 24 h, cells were seeded onto 100-mm culture dishes in a 1:5 dilution and grown for 2 weeks in medium containing 500 mg/ml G418 (Invitrogen). The neomycin-resistant colonies were fixed with 4% formaldehyde, and colony formation efficiency was examined by Giemsa staining (Sigma-Aldrich).
Soft agar assay
Anchorage-independent growth of KLF4 overexpressing SH-SY-5Y cells was examined using soft agar assay. The base layer consisted of 1% agarose (Invitrogen) in complete SH-SY-5Y medium. 5 Â 10 4 cells were mixed with soft agar composed of 0.4% agarose in complete medium and plated on top of the base layer in 35 mm culture dishes. Soft agar cultures were maintained at 37 1C for an additional 6 weeks and observed for the appearance of colonies with Olympus inverted Microscope CKX41 (Olympus, Hamburg, Germany).
Luciferase reporter assay p21 WAF1/CIP1 -Luc and p53-Luc reporter constructs were provided by Dr Willison Ching (University of Hong Kong). In total, 500 ng of expression plasmid DNA (pFLAG-CMV-KLF4, pFLAG-CMV-KLF4DA, pFLAG-CMV-KLF4DDBD or pFLAG-CMV expression vector), 200 ng of reporter constructs (p21-Luc or p53-Luc) and 25 ng of control Renilla luciferase construct (TK-RL-Luc) were transfected into 4 Â 10 4 SK-N-AS cells that were plated in a 24-well plate 16 h before the experiment. Cells were harvested according to the Promega Dual Luciferase Reporter assay kit protocol 24 h after transfection. Briefly, cells were washed with PBS, incubated in reporter lysis buffer and bioluminescence was measured using a Microplate Luminometer LB96V (Berthold Technology, Bad Wildbad, Germany). Reporter activity was normalized with Renilla luciferase activity to correct for variations in transfection efficiency.
Apoptosis 2 Â 10
5 SK-N-AS cells were transiently transfected with KLF4 expressing plasmids (pFLAG-CMV-KLF4, pFLAG-CMV-KLF4DA, pFLAG-CMV-KLF4DDBD) or pFLAG-CMV vector as described above. Ninety-six hours after transfection, dead and apoptotic cells were measured using Annexin V-FITC apoptosis detection kit from BD PharMingen (San Jose, CA, USA). Both adherent and floating cells were collected and subjected to Annexin V apoptosis assay. To detect the apoptotic cells, cells were resuspended in 1 Â cold binding buffer (10 mmol/l MgCl 2 , 4% BSA) and stained with FITC-conjugated anti-Annexin V antibody for analysis. Cells were also stained with propidium iodide to detect dead cells. Analyses were done on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) using CellQuest software (Becton Dickinson). Cells stained for Annexin V and propidium iodide were apoptotic.
Mouse xenograft studies A total of 1 Â 10 7 SH-SY-5Y stable transfectants or BE(2)C knockdown clones were injected subcutaneously in the flank of 5-to 6-week-old SCID/ Beige mice. The difference in tumor size between the vector control group and the KLF4 overexpressing group was assessed on day 90. The width and length of the tumor were measured and tumor volume was calculated with the equation: width Â (width/2) Â length. Average volume was then plotted in the bar chart. For BE(2)C knockdown clones, the tumor size was measured for 5 weeks. 1.5 Â 10 6 SH-SY-5Y stable transfectants mixed 1:3 with basement membrane extract (Trevigen, Gaithersburg, MD, USA) were also injected orthotropically into the adrenal fat pad of SCID/Beige mice (5 mice/group) and mice were killed on week 8. Three additional mice injected with KLF4 overexpressing or vector control cells were kept for 100 days. All procedures were approved by the University ethics committee for animal research (CULATR 2215-10). Experiments were terminated when tumors reached a maximum size of 15 mm diameter. After mice were killed, tumors were fixed in 4% paraformaldehyde, then paraffin-embedded and subjected to hematoxylin-eosin staining.
Differentiation assays
Fibromuscular lineage. To induce fibromuscular differentiation of NB cells, BE(2)C non-silencing control or the knockdown clones, cells were grown in media containing 10% serum and 10 mM BrdU (5-bromo-2-deoxyuridine) for 2 weeks. Media containing the drug were renewed three times per week. For immunocytochemistry, 1 Â 10 4 cells were plated into slides coated with poly-lysine (Invitrogen) and cultured for two additional days.
Neural lineage. To induce neural lineage differentiation of NB cells, cells were grown in full media containing 1 mM all-trans-retinoic acid (Sigma) for 4 weeks. Media containing the drug were renewed three times per week and cells were trypsinized at least once per week. A week before harvesting, 5 Â 10 4 cells were plated into a 35-mm-well and neural differentiation was monitored based on the formation of neurite outgrowth on week 4. For each treatment group, a minimum of 9 random fields under Â 100 magnification with at least 500 cells in total was photographed for cell counting. The values reported in bar charts represent the mean ± 95% confidence intervals (CIs) of three independent experiments.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde, stained with mouse anti-SMA (1:500; Sigma) or anti-paxillin (Upstate), and followed by host-appropriate FITC or Texas-Red secondary (Molecular Probes, Invitrogen, Eugene, OR, USA). The F-actin was visualized by tetramethylrhodamine B isothiocyanate (TRITC)-labeled phalloidin (Sigma). Cells were counterstained with DAKO mounting medium containing DAPI to detect nuclei. For SMA staining, a minimum of 9 random fields under Â 200 magnification with at least 250 cells in total per 35 mm-well from each treatment group was photographed for cell counting. The values reported in bar charts represent the mean±95% CIs of eighteen random fields from two wells and the experiments were repeated three times with four independent stable clones. Cells were photographed using a Nikon Eclipse E600 microscope (Nikon, Melville, NY, USA) with a Sony digital camera DSM1200F (Sony, Tokyo, Japan) under fluorescence illumination.
cDNA microarray and analysis
In all, 2 mg of total RNA was extracted from SH-SY-5Y cells stably transfected with pFLAG-CMV-KLF4 or pFLAG-CMV construct and microarray experiments were performed in triplicates using Human Genome U133 Plus 2.0 GeneChip from Affymetrix. For each array, preprocessing, normalization and analyses were performed identically for all samples, following the standard protocol provided by the manufacturer. Software GeneSpring (Affymetrix) was used for the subsequent data analysis. Genes were considered differentially expressed if the P-values were o0.01 and the fold changes were greater than twofold in either direction. Pathwaybased analyses were also performed and pathways were considered to be enriched in one group or the other (that is, control or KLF4 overexpressing cells) when one group had two or more genes within that pathway overexpressed than in the other group.
Statistical analysis
Statistical analysis was performed using the SPSS statistics software package (SPSS, Chicago, IL, USA). Statistical comparison for the KLF4 expression in patients between favorable and unfavorable groups was performed with Mann-Whitney U-test. Survival probabilities in various subgroups were estimated according to the Kaplan-Meier method. Survival distributions were compared using log-rank test. The Cox regression model was used to assess the prognostic significance of variables. Po0.05 was considered statistically significant.
The differences among multiple transfectants were analyzed with a two-sided unpaired Student's t-test using GraphPad Prism 5.00 (GraphPad Software, San Diego, CA, USA). A P-value of o0.05 was interpreted to represent a statistically significant difference. Experiments were usually replicated at least three times unless otherwise indicated and data are shown as means with 95% CIs. All statistical tests were two-sided.
